Squamous Non-Small Cell Lung Cancer Market Size, Share, Trends, Industry Analysis Report

Market Outlook

The global squamous non-small cell lung cancer market, valued at USD 9.3 billion in 2025, is projected to reach USD 10.0 billion in 2026 and USD 18.3 billion by 2035, representing a CAGR of 7.9% during the forecast period 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• In terms of therapeutic type, the immunotherapies segment holds the highest share (more than 35%) of the current market.
• Based on the drug class, the PD-1 / PD-L1 inhibitors segment holds the largest share of the current market.
• With respect to treatment line, the first-line treatment segment dominates (close to 60%) the current market.
• Based on the end-user, hospitals capture the largest share of the current market.
• In terms of geographical regions, North America currently holds the highest market share.

Key Market Statistics

• Market Size in 2026: $10.0 Billion
• Estimated Market Size in 2035: $18.3 Billion
• CAGR (2026-2035): 7.9%
• North America: Largest market in 2026
• Asia-Pacific: Fastest growing region

Market Introduction

Non-small cell lung cancer (NSCLC) represents the most common form of lung cancer, accounting for approximately 85% of all lung cancer cases worldwide. This broad category encompasses several histologic subtypes, with adenocarcinoma being the most prevalent, followed by squamous cell carcinoma. In NSCLC, cancer cells grow and spread more slowly than small cell lung cancer, providing a longer window for NSCLC treatment intervention.

Squamous NSCLC originates from squamous cells lining the lung airways and typically arises centrally in the larger bronchi, distinguishing it from adenocarcinoma, which tends to occur in the peripheral lung regions. This subtype is more strongly associated with tobacco smoking than other forms of NSCLC. Further, the incidence of squamous cell lung cancer has shown clear regional variations, with the highest age-standardized incidence rates occurring in central and eastern Europe and eastern Asia.

Drug developers are increasingly focusing on squamous NSCLC due to significant unmet medical needs and the limited treatment options specific to this subtype. Unlike adenocarcinoma, which has well-defined actionable mutations like EGFR, ALK, and ROS1, squamous NSCLC harbors fewer targetable driver mutations, making it resistant to traditional targeted therapies. Further, squamous NSCLC is increasingly being viewed as a separate commercial opportunity rather than a subset of NSCLC. Multiple late-stage trials are now targeting squamous NSCLC patients instead of the broader NSCLC population. Notably, BioNTech’s Phase III gotistobart study resumed recruitment exclusively for squamous NSCLC after data indicated divergent outcomes between squamous and non-squamous groups.

In the absence of suitable targeted therapies, immunotherapy with or without chemotherapy has become the cornerstone of squamous NSCLC treatment. However, survival-related outcomes remain poorer for patients with squamous NSCLC than in those with non-squamous NSCLC. This therapeutic gap has created a compelling opportunity for pharmaceutical innovation and prompted drug developers to work on advanced cancer therapeutics.

Top Drugs for the Treatment of Squamous Non-Small Cell Lung Cancer

Market Segmentation

Based on the research, we have segmented the Squamous Non-Small Cell Lung Cancer Market into therapeutic type, drug class, treatment line, end-user, and geographical regions.

By Therapeutic Type

• Immunotherapies
• Combination Therapies
• Chemotherapy
• Targeted Therapies
• Radiation Therapies

By Drug Class

• PD-1 / PD-L1 Inhibitors
• Platinum-based Drugs
• EGFR Inhibitors
• VEGF Inhibitors
• ALK Inhibitors

By Treatment Line

• First-line Treatment
• Second-line Treatment
• Adjuvant Therapies
• Third-line and Beyond Therapies
• Neoadjuvant Therapies

By End-User

• Hospitals
• Specialty Clinics
• Other End-Users

By Geographical Regions

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and North Africa

Squamous Non-Small Cell Lung Cancer Market Key Insights

What are the Key Drivers for Squamous Non-Small Cell Lung Cancer Market Growth?

• Rising Global Incidence of Squamous NSCLC: The incidence of squamous NSCLC continues to increase globally, particularly in regions with high smoking prevalence. Approximately 80% of cases in men and 90% in women are linked to tobacco use, and with the aging population worldwide, the patient pool requiring treatment is expanding. This has prompted several drug developers to manufacture safe and effective drugs for the treatment of squamous NSCLC.
• Advancements in Immunotherapy and New Drug Approvals: The emergence of PD-1 / PD-L1 checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, cemiplimab) has transformed squamous NSCLC treatment, offering superior survival outcomes compared to traditional chemotherapy. Further, multiple FDA approvals for first-line and second-line treatments have expanded therapeutic options, with immunotherapy combinations demonstrating significant survival benefits in clinical trials. This is driving widespread clinical adoption and market growth.

What are the Main Challenges for Market Growth?

• Limited Targeted Therapy Options: Unlike adenocarcinoma, squamous NSCLC has fewer targetable driver mutations (EGFR, ALK, ROS1), making it resistant to traditional targeted therapies. Several effective treatments used for non-squamous NSCLC, such as bevacizumab and pemetrexed, are contraindicated in squamous NSCLC due to safety concerns including hemorrhage risk. Differences in mutational landscapes and a lack of matched targeted therapies specific to squamous NSCLC oncogenic aberrations present additional limitations, creating a significant therapeutic gap.
• Poorer Survival Outcomes Compared to Non-Squamous NSCLC: In the absence of suitable targeted therapies, immunotherapy with or without chemotherapy is majorly used for the treatment of squamous NSCLC. However, survival-related outcomes remain poorer for patients suffering from squamous NSCLC. This disparity, combined with the lack of PD-L1 expression in many squamous tumors, and current immunotherapy options being tailored only to high-expressing tumors, limits the effectiveness of available treatments and hinders market growth.

Recent Developments in Squamous Non-Small Cell Lung Cancer Market

• In May 2026, Akeso (in partnership with Summit Therapeutics) reported positive overall survival results from the Phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy in first-line advanced squamous non-small cell lung cancer.
• In May 2026, Nuvation Bio announced the FDA acceptance of a supplemental new drug application for taletrectinib (IBTROZI) in advanced ROS1-positive non-small cell lung cancer.
• In March 2026, Eisai and Nuvation Bio announced that the European Medicines Agency validated the marketing authorization application for taletrectinib targeting advanced ROS1-positive non-small cell lung cancer.

Industry Experts on Squamous Non-Small Cell Lung Cancer Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following third-party discussions:

• Professor of Medicine and Medical Oncology and Chair in Cancer Research, Very Large Organization, US
• Co-chair, Very Large Organization, US
• Surgical Director of the Thoracic Oncology Program, Very Large Organization, US; Nurse Practitioner Specializing in Lung Cancer, Very Large Organization, US; Professor of Medicine, Very Large Organization, US
• Thoracic Medical Oncologist & Early Drug Development Specialist, Very Large Organization, US
• Thoracic Medical Oncologist, Very Large Organization, US
• Thoracic Medical Oncologist, Very Large Organization, US
• Medical Oncologist, Very Large Organization, US
• Co-founder, Small Organization, US
• Pulmonologist and Professor of Medicine, Very Large Organization, US
• Thoracic Medical Oncologist, Very Large Organization, US

Market Share Insights

Which Therapeutic Type Accounts for the Largest Share of the Overall Market?

This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various therapeutic types, such as immunotherapies, combination therapies, chemotherapy, targeted therapies and radiation therapies.

Currently, the immunotherapies subsegment captures the majority (more than 35%) of the market share. This is due to their ability to significantly improve survival outcomes and provide durable responses compared to traditional chemotherapy. The introduction of immune checkpoint inhibitors targeting the PD-1, PD-L1, and CTLA-4 pathways and immunocytokines has transformed the treatment landscape for squamous NSCLC, particularly in advanced and metastatic settings where targeted therapy options are relatively limited.

Further, the market for immunotherapies is expected to grow at a faster pace as these therapies have become a standard of care across multiple lines of treatment, either as monotherapy or in combination with chemotherapy. This can be attributed to their demonstrated efficacy, favorable benefit-risk profile, and broad applicability across patient populations. Moreover, strong clinical evidence and an increasing number of regulatory approvals for immunotherapy-based regimens have contributed to the segment's dominant market position.

Which Drug Class Accounts for the Largest Share of Squamous Non-Small Cell Lung Cancer Market?

This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various drug classes, such as PD-1 / PD-L1 inhibitors, platinum-based drugs, EGFR inhibitors, VEGF inhibitors and ALK inhibitors.

Currently, the PD-1 / PD-L1 inhibitor subsegment captures the majority of the market share. This is because they have become a cornerstone of treatment across multiple disease stages and lines of therapy. Further, these immunotherapies work by restoring the immune system's ability to recognize and attack tumor cells, resulting in improved overall survival rates and better clinical outcomes when compared to conventional chemotherapy. Further, their broad applicability in patients with advanced squamous NSCLC has led to its widespread adoption in clinical practice.

Notably, the PD-1 / PD-L1 inhibitor segment is expected to grow at a significant pace during the forecast period due to the continued expansion of immunotherapy indications and increasing utilization across earlier stages of squamous NSCLC. Further, ongoing clinical trials are evaluating novel combination strategies involving PD-1 / PD-L1 inhibitors with chemotherapy, targeted therapies, and other immunotherapeutic agents. This is expected to further improve treatment outcomes and expand eligible patient populations.

Which Treatment Line Accounts for the Largest Share in the Squamous Non-Small Cell Lung Cancer Market?

This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various treatment lines, such as first-line treatment, second-line treatment, adjuvant therapies, third-line and beyond therapies, and neoadjuvant therapies.

Currently, the first-line treatment segment occupies the highest market share (close to 60%). This can be attributed to the fact that it represents the initial and most widely utilized treatment setting for the majority of newly diagnosed patients with advanced diseases. Further, these regimens have demonstrated meaningful improvements in overall survival, progression-free survival, and response rates when compared with historical chemotherapy-only approaches. Further, it is important to note that nearly all eligible patients receive first-line systemic therapy, while only a small number of patients proceed to later treatment lines due to disease progression, clinical status, or mortality. This results in increased patient volume and treatment duration in the first-line treatment setting, resulting in the highest market value contribution.

The market for neoadjuvant therapies is expected to grow at a significant pace during the forecast period owing to the expanding use of preoperative systemic treatment in resectable and potentially resectable squamous NSCLC. Additionally, clinical studies have shown that neoadjuvant immunotherapy-based regimens can increase pathologic response rates, reduce residual tumour burden, and improve event-free survival before surgery. As regulatory approvals and treatment guidelines increasingly incorporate neoadjuvant immunotherapy approaches, more patients are becoming eligible for therapy earlier in the disease course, consequently contributing towards a higher growth rate.

Market Share by End-User: Hospitals Segment to Hold the Highest Revenue

This segment highlights the distribution of market value for squamous non-small cell lung cancer drugs across various end-users, such as hospitals, specialty clinics and other end-users.

Hospitals hold the largest share of the squamous NSCLC market because they serve as the primary centers for diagnosis, staging, treatment initiation, and long-term management of lung cancer patients. The treatment of squamous NSCLC often requires a multidisciplinary approach involving oncologists, pulmonologists, thoracic surgeons, radiologists, pathologists, and specialized nursing teams, all of which are typically available within hospital settings. In addition, hospitals are the main providers of complex and high-cost therapies, including immunotherapies, chemotherapy, combination regimens, surgery, and radiation therapy.

The specialty clinics segment is expected to grow at a significant pace during the forecast period, owing to the increasing shift toward outpatient cancer care and the growing demand for specialized oncology services. Notably, these clinics offer focused expertise in cancer management and convenient access to advanced therapies, including immunotherapies and targeted treatments. Further, improvements in treatment administration and monitoring have enabled many therapies to be delivered safely in outpatient settings, thereby reducing the need for prolonged hospital visits.

Regional Analysis: Which Regions are Showing the Fastest Growth in Squamous Non-Small Cell Lung Cancer Industry?

North America: Dominating the Market by Securing Highest Share

According to our projections, North America is likely to capture the majority of the market share in the current year. This can be attributed to its advanced healthcare infrastructure, high adoption of innovative oncology therapies, and strong presence of leading pharmaceutical and biotechnology companies. In addition, favorable reimbursement frameworks and strong clinical research activity have accelerated the uptake of newly approved therapies within this region.

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at the highest CAGR during the forecast period. This is due to the rising incidence of lung cancer, expanding healthcare access, and increasing investments in cancer care infrastructure across countries such as China, India, Japan, and South Korea. Further, continued exposure to high-risk factors such as smoking and air pollution is rapidly contributing to a growing patient pool in the region.

Scope of Squamous Non-Small Cell Lung Cancer Market Report

Key Report Attribute	Details
Historical Trend	Since 2019
Forecast Period	Till 2035
Market Size 2026	$ 10.0 Billion
Market Size 2035	$ 18.3 Billion
CAGR (Till 2035)	7.9%
Segments Covered	Therapeutic Type Drug Class Treatment Line End-User Geographical Regions
Key Squamous Non-Small Cell Lung Cancer Drugs Profiled	Necitumumab Pembrolizumab Nivolumab Cemiplimab Ipilimumab Atezolizumab (A complete list of players captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available